Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Fresenius Kabi USA, LLC
483
•Fresenius Kabi USA, LLC•July 8, 2011

Fresenius Kabi USA, LLC – FDA 483, Jul 8, 2011

Record Details

An FDA inspection conducted at APP Pharmaceuticals, LLC, a sterile drug manufacturer in Grand Island, NY, from June 13 to July 8, 2011, revealed significant deviations from Current Good Manufacturing Practice (cGMP) regulations. The inspection identified numerous systemic issues spanning quality systems, facility controls, laboratory operations, and post-market reporting. Key findings included a widespread failure to thoroughly investigate over 400 customer complaints since January 2010, involving critical issues such as particulate matter, product discoloration, cracked/leaking vials, and foreign objects like insects. The company did not consistently perform initial impact assessments or adequately attempt to collect complaint samples, nor did it file required NDA-Field Alert Reports for these significant product quality concerns. Further observations highlighted inadequate environmental controls, with multiple instances of insect contamination in aseptic manufacturing areas. Procedures designed to prevent microbiological contamination, such as media fill documentation and vent filter integrity testing, were found deficient or not followed. Laboratory controls were also cited for scientifically unsound sampling plans, insufficient acceptance criteria for particulate matter testing, and the use of unverified analytical methods and computer systems. Records for returned drug products were not properly maintained, and master production records lacked complete instructions, leading to deviations. The FDA requires APP Pharmaceuticals, LLC to address these serious compliance deficiencies with comprehensive corrective and preventive actions to ensure the safety, quality, and integrity of its sterile drug products.

Company
Fresenius Kabi USA, LLC
Inspection date
July 8, 2011
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Kevin A. Gonzalez (Branch Chief, Foreign Pharmaceutical Quality Inspection at FDA)
  • Felix Maldonado (Chemist at US Department of Health and Human Services)
  • James D. Bridges
View Company Profile

ID · a396774c-8281-464e-859d-99698920571c

Other documents for Fresenius Kabi USA, LLC
  • 483 - 2026-05-14May 14, 2026
  • 483 - 2023-10-13October 13, 2023
  • 483 - 2023-08-30August 30, 2023
  • 483 - 2019-08-12August 12, 2019
  • EIR - 2019-08-12August 12, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Fresenius Kabi USA, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.